New drug cocktail aims to boost lymphoma remission
NCT ID NCT07505849
First seen Apr 23, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This study compares two treatment combinations for people newly diagnosed with follicular lymphoma, a slow-growing blood cancer. One group gets the standard R2 regimen (rituximab and lenalidomide), while the other adds zanubrutinib (ZR2). The goal is to see if the three-drug combo leads to more complete remissions. About 100 adults will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.